Immanuel F Luescher |
|
|
|
Université de Lausanne
·
Centre Ludwig pour la recherche sur le cancer
|
Publications (40) View all
-
Article: An optimised method for establishing high purity murine CD8(+) T cells cultures.
[show abstract] [hide abstract]
ABSTRACT: Establishing CD8(+) T cell cultures has been empirical and the published methods have been largely individual laboratory based. In this study, we optimized culturing conditions and show that IL-2 concentration is the most critical factor for the success of establishing CD8(+) T cell cultures. High IL-2 concentration encouraged T cells to non-specifically proliferate, express a B cell marker, B220, and undergo apoptosis. These cells also lose typical irregular T cell morphology and are incapable of sustaining long-term cultures. Using tetramer and intracellular cytokine assessments, we further demonstrated that many antigen-specific T cells have been rendered nonfunctional when expanded under high IL-2 concentration. When IL-2 is used in the correct range, B220-mediated cell depletion greatly enhanced the success rate of such T cell cultures.Journal of immunological methods 10/2012; · 2.35 Impact Factor -
SourceAvailable from: Weisan Chen
Article: A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen.
Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Heather M Jackson, Nektaria Dimopoulos, Philippe Guillaume, Ashley J Knights, Tamara Lowen, Neil C Robson, Sarah E Russell, Emmanuel Scotet, Ian D Davis, Eugene Maraskovsky, Jonathan Cebon, Immanuel F Luescher, Weisan Chen[show abstract] [hide abstract]
ABSTRACT: NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8(+) T cell epitope, NY-ESO-1(88-96) (LEFYLAMPF) and compared its direct- and cross-presentation to that of the reported NY-ESO-1(157-165) epitope restricted to HLA-A*0201. Although both epitopes were readily cross-presented by DCs exposed to various forms of full-length NY-ESO-1 antigen, remarkably NY-ESO-1(88-96) is much more efficiently cross-presented from the soluble form, than NY-ESO-1(157-165). On the other hand, NY-ESO-1(157-165) is efficiently presented by NY-ESO-1-expressing tumor cells and its presentation was not enhanced by IFN-γ treatment, which induced immunoproteasome as demonstrated by Western blots and functionally a decreased presentation of Melan A(26-35); whereas NY-ESO-1(88-96) was very inefficiently presented by the same tumor cell lines, except for one that expressed high level of immunoproteasome. It was only presented when the tumor cells were first IFN-γ treated, followed by infection with recombinant vaccinia virus encoding NY-ESO-1, which dramatically increased NY-ESO-1 expression. These data indicate that the presentation of NY-ESO-1(88-96) is immunoproteasome dependent. Furthermore, a survey was conducted on multiple samples collected from HLA-B18(+) melanoma patients. Surprisingly, all the detectable responses to NY-ESO-1(88-96) from patients, including those who received NY-ESO-1 ISCOMATRIX™ vaccine were induced spontaneously. Taken together, these results imply that some epitopes can be inefficiently presented by tumor cells although the corresponding CD8(+) T cell responses are efficiently primed in vivo by DCs cross-presenting these epitopes. The potential implications for cancer vaccine strategies are further discussed.PLoS ONE 01/2012; 7(9):e44707. · 4.09 Impact Factor -
Article: CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Philippe Guillaume, Immanuel F Luescher, Cindy Sander, John M Kirkwood, Daniel Olive, Vijay Kuchroo, Hassane M Zarour[show abstract] [hide abstract]
ABSTRACT: Cytotoxic T cells that are present in tumors and capable of recognizing tumor epitopes are nevertheless generally impotent in eliciting tumor rejection. Thus, identifying the immune escape mechanisms responsible for inducing tumor-specific CD8(+) T-cell dysfunction may reveal effective strategies for immune therapy. The inhibitory receptors PD-1 and Tim-3 are known to negatively regulate CD8(+) T-cell responses directed against the well-characterized tumor antigen NY-ESO-1. Here, we report that the upregulation of the inhibitory molecule BTLA also plays a critical role in restricting NY-ESO-1-specific CD8(+) T-cell expansion and function in melanoma. BTLA-expressing PD-1(+)Tim-3(-) CD8(+) T cells represented the largest subset of NY-ESO-1-specific CD8(+) T cells in patients with melanoma. These cells were partially dysfunctional, producing less IFN-γ than BTLA(-) T cells but more IFN-γ, TNF, and interleukin-2 than the highly dysfunctional subset expressing all three receptors. Expression of BTLA did not increase with higher T-cell dysfunction or upon cognate antigen stimulation, as it does with PD-1, suggesting that BTLA upregulation occurs independently of functional exhaustion driven by high antigen load. Added with PD-1 and Tim-3 blockades, BTLA blockade enhanced the expansion, proliferation, and cytokine production of NY-ESO-1-specific CD8(+) T cells. Collectively, our findings indicate that targeting BTLA along with the PD-1 and Tim-3 pathways is critical to reverse an important mechanism of immune escape in patients with advanced melanoma.Cancer Research 12/2011; 72(4):887-96. · 7.86 Impact Factor -
Article: Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Julien Schmidt, Philippe Guillaume, Melita Irving, Petra Baumgaertner, Daniel Speiser, Immanuel F Luescher[show abstract] [hide abstract]
ABSTRACT: MHC-peptide multimers containing biotinylated MHC-peptide complexes bound to phycoerythrin (PE) streptavidin (SA) are widely used for analyzing and sorting antigen-specific T cells. Here we describe alternative T cell-staining reagents that are superior to conventional reagents. They are built on reversible chelate complexes of Ni(2+)-nitrilotriacetic acid (NTA) with oligohistidines. We synthesized biotinylated linear mono-, di-, and tetra-NTA compounds using conventional solid phase peptide chemistry and studied their interaction with HLA-A*0201-peptide complexes containing a His(6), His(12), or 2×His(6) tag by surface plasmon resonance on SA-coated sensor chips and equilibrium dialysis. The binding avidity increased in the order His(6) < His(12) < 2×His(6) and NTA(1) < NTA(2) < NTA(4), respectively, depending on the configuration of the NTA moieties and increased to picomolar K(D) for the combination of a 2×His(6) tag and a 2×Ni(2+)-NTA(2). We demonstrate that HLA-A2-2×His(6)-peptide multimers containing either Ni(2+)-NTA(4)-biotin and PE-SA- or PE-NTA(4)-stained influenza and Melan A-specific CD8+ T cells equal or better than conventional multimers. Although these complexes were highly stable, they very rapidly dissociated in the presence of imidazole, which allowed sorting of bona fide antigen-specific CD8+ T cells without inducing T cell death as well as assessment of HLA-A2-peptide monomer dissociation kinetics on CD8+ T cells.Journal of Biological Chemistry 12/2011; 286(48):41723-35. · 4.77 Impact Factor -
Article: Reversible MHC I-peptide multimers containing Ni2+NTA peptides and his tags improve analysis and sorting of CD8+ T cells
Julien Schmidt, Philippe Guillaume, Melita Irving, Petra Baumgaertner, Daniel Speiser, Immanuel F. Luescher[show abstract] [hide abstract]
ABSTRACT: MHC-peptide multimers containing biotinylated MHC-peptide complexes bound to phycoerythrin streptavidin (PE SA) are widely used for analyzing and sorting antigen-specific T cells. Here we describe alternative T cell staining reagents that are superior to conventional reagents. They are built on reversible chelate complexes of Ni2+ nitrilotriacetic acid (NTA) with oligo-histidines. We synthesized biotinylated linear mono, di and tetra NTA compounds using conventional solid phase peptide chemistry and studied their interaction with HLA-A*0201-peptide complexes containing a His6, His12 or a 2xHis6 tag by surface plasmon resonance on SA coated sensor chips and equilibrium dialysis. The binding avidity increased in the order His6 < His12 < 2xHis6 and NTA1 < NTA2 < NTA4, respectively, depended on the configuration of the NTA moieties and increased to pico-molar KD for the combination of a 2xHis6 His tag and a 2xNi2+NTA2. We demonstrate that HLA-A2-2xHis6-peptide multimers containing either Ni2+ NTA4-biotin and PE-SA or PE-NTA4 stained influenza and Melan-A-specific CD8+ T cells equal of better than conventional multimers. While these complexes were highly stable, they very rapidly dissociated in the presence of imidazole, which allowed sorting of bona fide antigen-specific CD8+ T cells without inducing T cell death as well as assessment of HLA-A2-peptide monomer dissociation kinetics on CD8+ T cells.Journal of Biological Chemistry 10/2011; · 4.77 Impact Factor